Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.

Context: Short stature in children may be associated with low IGF-I despite normal stimulated GH levels and without other causes.

Objective: Our objective was to assess the safety and efficacy of recombinant human IGF-I (rhIGF-I) in short children with low IGF-I levels.

Design: This was a 1-yr, randomized, open-label trial (MS301).

The role of the primary care physician in caring for patients with type-1 diabetes.

The management of type-1 diabetic patients is a challenge. Given the natural frequency of this medical problem, most primary care providers will have such patients in their office-based practice. The push for tighter control in order to lessen long-term complications is a sensible move, but it does not inherently require that you absent yourself from the loop.

Human growth hormone treatment of children with growth failure and normal growth hormone levels by immunoassay: lack of correlation with somatomedin generation.

Children with growth failure, normal growth hormone responses to stimulation tests, and low somatomedin levels are being recognized with increasing frequency. Sixteen patients, aged 2 to 17 years, with these findings were studied. When treated with human growth hormone, the mean plasma somatomedin-C levels of these patients increased from 0.

Galactorrhea in a 12-year-old boy with a chromophobe adenoma.

A 12-year-old with galactorrhea is presented. He was in early puberty, had gynecomastia, and was markedly obese. Roentgenograms of the skull showed an asymmetrically enlarged sella trucica, but pneumoencephalography did not indicate suprasellar extension of the pituitary tumor.